The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study

Emanuele D'Amico; C. Leone; Giusi Graziano; Maria Pia Amato; Roberto Bergamaschi; P. Cavalla; G. Coniglio; Giancarlo Di Battista; Maria T. Ferrò; Franco Granella; Enrico Granieri; Alessandra Lugaresi; G. Lus; E. Millefiorini; C. Pozzilli; G. Tedeschi; Mario Zappia; Giancarlo Comi; Maria Trojano; V. Lepore; Francesco Patti

doi:10.1371/journal.pone.0157721

The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study

Emanuele D'Amico, C. Leone, Giusi Graziano, Maria Pia Amato, Roberto Bergamaschi, P. Cavalla, G. Coniglio, Giancarlo Di Battista, Maria T. Ferrò, Franco Granella, Enrico Granieri, Alessandra Lugaresi, G. Lus, E. Millefiorini, C. Pozzilli, G. Tedeschi, Mario Zappia, Giancarlo Comi, Maria Trojano, V. LeporeFrancesco Patti

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS? Methods We conducted a retrospective multicentre study to investigate the frequency of ISA prescription in 17 Italian MS centres, and to describe the clinical factors related to ISA use. Results Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the most frequently used ISA overall. MS patients treated with ISA alone were more frequently affected by the progressive course (both primary and secondary) of the disease (RRR 5.82, 95% CI 4.14-8.16, p

Original language	English
Article number	e0157721
Journal	PLoS One
Volume	11
Issue number	6
DOIs	https://doi.org/10.1371/journal.pone.0157721
Publication status	Published - Jun 1 2016

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

Access to Document

10.1371/journal.pone.0157721

Cite this

D'Amico, E., Leone, C., Graziano, G., Amato, M. P., Bergamaschi, R., Cavalla, P., Coniglio, G., Di Battista, G., Ferrò, M. T., Granella, F., Granieri, E., Lugaresi, A., Lus, G., Millefiorini, E., Pozzilli, C., Tedeschi, G., Zappia, M., Comi, G., Trojano, M., ... Patti, F. (2016). The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study. PLoS One, 11(6), [e0157721]. https://doi.org/10.1371/journal.pone.0157721

D'Amico, E, Leone, C, Graziano, G, Amato, MP, Bergamaschi, R, Cavalla, P, Coniglio, G, Di Battista, G, Ferrò, MT, Granella, F, Granieri, E, Lugaresi, A, Lus, G, Millefiorini, E, Pozzilli, C, Tedeschi, G, Zappia, M, Comi, G, Trojano, M, Lepore, V & Patti, F 2016, 'The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study', PLoS One, vol. 11, no. 6, e0157721. https://doi.org/10.1371/journal.pone.0157721

@article{f18e43b0682c461a96d3420e049d70a7,

title = "The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study",

abstract = "Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS? Methods We conducted a retrospective multicentre study to investigate the frequency of ISA prescription in 17 Italian MS centres, and to describe the clinical factors related to ISA use. Results Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the most frequently used ISA overall. MS patients treated with ISA alone were more frequently affected by the progressive course (both primary and secondary) of the disease (RRR 5.82, 95% CI 4.14-8.16, p",

author = "Emanuele D'Amico and C. Leone and Giusi Graziano and Amato, {Maria Pia} and Roberto Bergamaschi and P. Cavalla and G. Coniglio and {Di Battista}, Giancarlo and Ferr{\`o}, {Maria T.} and Franco Granella and Enrico Granieri and Alessandra Lugaresi and G. Lus and E. Millefiorini and C. Pozzilli and G. Tedeschi and Mario Zappia and Giancarlo Comi and Maria Trojano and V. Lepore and Francesco Patti",

year = "2016",

month = jun,

day = "1",

doi = "10.1371/journal.pone.0157721",

language = "English",

volume = "11",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "6",

}

TY - JOUR

T1 - The use of immunosuppressant therapy for multiple sclerosis in Italy

T2 - A multicenter retroprospective study

AU - D'Amico, Emanuele

AU - Leone, C.

AU - Graziano, Giusi

AU - Amato, Maria Pia

AU - Bergamaschi, Roberto

AU - Cavalla, P.

AU - Coniglio, G.

AU - Di Battista, Giancarlo

AU - Ferrò, Maria T.

AU - Granella, Franco

AU - Granieri, Enrico

AU - Lugaresi, Alessandra

AU - Lus, G.

AU - Millefiorini, E.

AU - Pozzilli, C.

AU - Tedeschi, G.

AU - Zappia, Mario

AU - Comi, Giancarlo

AU - Trojano, Maria

AU - Lepore, V.

AU - Patti, Francesco

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS? Methods We conducted a retrospective multicentre study to investigate the frequency of ISA prescription in 17 Italian MS centres, and to describe the clinical factors related to ISA use. Results Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the most frequently used ISA overall. MS patients treated with ISA alone were more frequently affected by the progressive course (both primary and secondary) of the disease (RRR 5.82, 95% CI 4.14-8.16, p

AB - Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS? Methods We conducted a retrospective multicentre study to investigate the frequency of ISA prescription in 17 Italian MS centres, and to describe the clinical factors related to ISA use. Results Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the most frequently used ISA overall. MS patients treated with ISA alone were more frequently affected by the progressive course (both primary and secondary) of the disease (RRR 5.82, 95% CI 4.14-8.16, p

UR - http://www.scopus.com/inward/record.url?scp=84978139141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978139141&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0157721

DO - 10.1371/journal.pone.0157721

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0157721

ER -

The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this